Korea Economic Institute of America的动态

Andrew Tindall shines a spotlight on the often overlooked but incredibly valuable domain of trade secrets in biotech in his latest article. Dive into the EU Trade Secrets Directive, grasp what's protectable, and discover how to secure your innovations with our SafeGuard - Trade Secrets Audit & Protection service. Find out more in our latest article ?? https://lnkd.in/ewh4VB-d #Biotech #IntellectualProperty #TradeSecrets

Have a closer look to Europe's threats in biomanufacturing ?? ? Biotech has often been subject to politically-driven decision making, unconnected to scientific evidence. ? The growing global protectionism may pose challenges due to Europe's reliance on external inputs. ? Despite #biotech widespread use, it is vital that public understanding is continuously developed. ? A global race to mature #biomanufacturing is ongoing, with key countries positioning themselves through investments and targets. ?? Read the full report at: https://bit.ly/3wGtyMo

Innovative biotech and biomanufacturing are very important for Europe’s green transition. With its innovative power and by creating new industrial ecosystems, the bio-based industries sector is a strategic pillar for biomanufacturing in Europe today. We hope that the new EU Parliament and EU Commission will be bold on turning the EU Communication, "Building the future with nature: Boosting Biotechnology and Biomanufacturing in the EU" into reality! Read our reaction to an ???? Bio-Initiative ?? https://zurl.co/cB5e

"...the complex world of China’s hybrid economic system that blurs private and public, civilian and military to meet the goals of the State. This system creates market distortions and undermines the global norms of science by leveraging researchers as well as academic and commercial entities to further national priorities, rather than open, mutually beneficial collaborations or fair commercial competition that fosters innovation and is free from market-distorting subsidies and restrictions. Through its policies and programs, China uses the power of the State to not only advantage its own companies but to disadvantage others, with the goal of dominating these industries of the future. "Despite the importance of genomics and initial investments into the Human Genome Project, the U.S. still lacks a comprehensive national strategy for the bioeconomy. China will gain an advantage in technology competition if we don’t acknowledge and address those areas where national security and market forces diverge. The early stages of development for these new knowledge-based industries—such as biotechnology—will be most critical for government support and policies."

?? The latest US restrictions on Chinese biotech are making waves in the global tech landscape. As China Week kicks off, this article sheds light on how these new regulations could impact innovation and collaboration in the biotech sector. ?? ?? Check out TechRadar's deep dive for more insights #ChinaWeek #Biotech #TechNews #Innovation #GlobalMarkets #Regulations #USChinaRelations

We heard a lot of interesting (and varying) opinions about the pending “BIOSECURE ACT” coming out of the BIO 2024 Conference this week. The most recent House amendment grants an 8-year grandfathering provision for existing contracts with Chinese companies “of concern.” Even still, if this bill passes, life sciences companies are going to need to consider their supply and service relationships now in order to avoid potential future compliance risks with the U.S. government -- and possible retaliatory responses by the Chinese government. ? Please reach out if you would like to discuss and check out our white paper on the BIOSECURE Act below: #BournePartners #InvestmentBanking #BourneBreif #Biotech #BiosecureAct #SupplyChain #BIO2024 #Legislation U.S. House of Representatives

? ???????????????????? ????????????????????: ?????? ???????????? ???? ?????????????? ???? ???????????????????? ???????? ???????????????????? ???? ?????????????? ?????????????????? Today, in our final video in the series, we look at how changes to #RDP will impact innovative #biotech companies. RDP is often crucial to smaller innovators who use RDP to gain a competitive edge to help offset the challenges faced by these smaller innovators. Decreasing this kind of protection would significantly impact the ability of these companies to compete fairly and to deal with the unique challenges they face. ?? Find out more here https://lnkd.in/eHZMiaHU

Webinar: Are Regulations Finally Bringing the Bioplastics Revolution?: Thursday 10 October 2024 - An overview of bioplastics; How new Chinese regulations are transforming the industry; How other countries are approaching bioplastics regulations; The changing landscape of bioplastic applications; Why bio-composites using bioplastics are seeing increased interest and their challenges; IDTechEx's outlook and conclusions https://dlvr.it/TDtFz2

The BIOSECURE Act,?was passed on Monday 9th September by the US House of Representatives. It?is designed to prevent U.S.?companies from working with certain Chinese biotech service providers over national security concerns.?Read the details of the act in our recent blog: https://lnkd.in/eyqpNcU9 This development is significant because it highlights increasing geopolitical tensions and concerns about intellectual property theft and potential espionage.?While the bill enjoys bipartisan support,?it faces criticism for potentially harming U.S.?innovation and disrupting critical relationships with Chinese partners in the life sciences industry.?The fate of the bill now rests with the Senate,?but regardless of the outcome,?it signals a potential shift in U.S.-China collaboration in the biotech sector. The bill has the capacity to have wider consequences to the life science supply chain globally. Biosynth's mission is to provide a secure life science supply chain with end to end services from sites in the US and Europe which has never been more critical to our customers.?If you are concerned about your future sourcing and collaboration on projects, contact us today. www.biosynth.com/contact #biosecureact #biotech #supplychain #uschina

What can the #biotech industry learn from other fields to create new biomanufacturing processes with reduced negative environmental & financial impact? Learn about the potential impact of current innovations during our FREE #ACSWebinar. Register at https://brnw.ch/21wHpG3